As Medicare Part D enters its 20th year in 2026, utilization management is a significant and growing factor that affects patient access to prescription medications and can lead to claim rejections, treatment delays and interruptions in care. Even though certain therapeutic classes have protected coverage, and some brands even have coverage requirements, patients may still face restrictions that result in their claims being rejected.

Join IQVIA experts for an analysis of utilization management trends across Medicare Part D, including longitudinal patient data on time-to-approval and therapy switching. The session will also explore the impact of utilization management across a range of therapeutic areas including oncology, HIV, and immunology.